I-BET151 (GSK1210151A)

Catalog No.S2780

I-BET151 (GSK1210151A) Chemical Structure

Molecular Weight(MW): 415.44

I-BET151 (GSK1210151A) is a novel selective BET inhibitor for BRD2, BRD3 and BRD4 with IC50 of 0.5 μM, 0.25 μM, and 0.79 μM in cell-free assays, respectively.

Size Price Stock Quantity  
USD 170 In stock
USD 270 In stock
USD 870 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

2 Customer Reviews

  • OVTOKO and OVCA420 cells were treated with DMSO, JQ1 (1 μM) or I-BET151 (1 μM). Cell lysates were immunoblotted with indicated antibodies.

    Theranostics, 2016, 6(2):219-30.. I-BET151 (GSK1210151A) purchased from Selleck.

    B. Western blot analysis of pERK and ERK in cells treated with JQ1 or I-BET151.

    Oncotarget, 2016, 7(3):2545-54. I-BET151 (GSK1210151A) purchased from Selleck.

Purity & Quality Control

Choose Selective Epigenetic Reader Domain Inhibitors

Biological Activity

Description I-BET151 (GSK1210151A) is a novel selective BET inhibitor for BRD2, BRD3 and BRD4 with IC50 of 0.5 μM, 0.25 μM, and 0.79 μM in cell-free assays, respectively.
Features Optimized to retain excellent BET target potency and selectivity while enhancing the in vivo pharmacokinetics and terminal half-life to enable prolonged in vivo studies.
Targets
BRD3 [1]
(Cell-free assay)
BRD2 [1]
(Cell-free assay)
BRD4 [1]
(Cell-free assay)
0.25 μM 0.5 μM 0.79 μM
In vitro

I-BET151 exhibits potent selectivity over an extensive range of diverse protein types such as COX-2, P450, Aurora B, GSK3β, PI3K-γ, GPCR, ion channels, and transporters. Similar to I-BET762 (GSK525762A), I-BET151 displays potent binding affinity to BRD2, BRD3 and BRD4 with KD of 0.02-0.1 μM, and significantly inhibits lipopolysaccharide-stimulated IL-6 cytokine production in human peripheral blood mononuclear cells (PBMC) and whole blood (WB) as well as rat WB with IC50 of 0.16 μM, 1.26 μM, and 1.26 μM, respectively. I-BET151 (0.5 or 5 μM) inhibits the binding of BETs (BRD2, BRD3, BRD4, and BRD9) but not the binding of 23 other bromodomain proteins in HL60 nuclear extract to acetylated histone peptides. I-BET151 has potent efficacy against cell lines harboring different MLL-fusions such as MV4;11, RS4;11, MOLM13, and NOMO1 cells with IC50 of 15-192 nM. Consistently, I-BET151 completely ablates the colony-forming potential of MLL-fusion-driven leukaemias (MOLM13) but not leukaemias driven by tyrosine kinase activation (K562). I-BET151 also displays potent efficacy in both liquid culture and clonogenic assays using primary murine progenitors transformed with either MLL-ENL or MLL-AF9. I-BET151 treatment significantly induces apoptosis and prominent G0/G1 arrest in MLL-fusion cell lines driven by distinct MLL fusions (MOLM13 and MV4;11 containing MLL-AF9 and MLL-AF4, respectively) but not the K562 cells, probably due to the inhibition of transcription of BCL2, C-MYC and CDK6 by blocking the recruitment of BRD3/4, PAFc and SEC components into transcriptional start site (TSS). [1]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
MV4;11 NVvnfmJp[3m2b4TvfIlkcXS7IHHzd4F6 MnnZglExOCEQvF2= MXzEUXNQ MnzhTWM2OD1{NjDuUS=> NGrBZZQzOTl4NEO0NC=>
RS4;11 NV:5SmpQ[3m2b4TvfIlkcXS7IHHzd4F6 MWP+NVAxKM7:TR?= MmTDSG1UVw>? MXXJR|UxRTF7MjDuUS=> MViyNVk3PDN2MB?=
MOLM13 MYDjfZRwfG:6aXPpeJkh[XO|YYm= Ml\uglExOCEQvF2= M2rLSmROW09? NVTGbnJZUUN3ME2xNlAhdk1? MXKyNVk3PDN2MB?=
NOMO1 NVrKbmtn[3m2b4TvfIlkcXS7IHHzd4F6 NHPFWHJ,OTByIN88US=> M1LaVmROW09? MYDJR|UxRTF3IH7N NYG4dlY1OjF7NkSzOFA>
HEL NID3PWlkgXSxdH;4bYNqfHliYYPzZZk> NXW3foVDhjFyMDFOwG0> NXXnPFhWTE2VTx?= MV\JR|UxRTFizszN NYLKboM{OjF7NkSzOFA>
K562 MWrjfZRwfG:6aXPpeJkh[XO|YYm= MV3+NVAxKM7:TR?= M37QPWROW09? NV3kWFhqUUN3ME6xNFAh|ryP NUPScGh2OjF7NkSzOFA>
MEG01 NECxRoVkgXSxdH;4bYNqfHliYYPzZZk> NIXHO21,OTByIN88US=> NH\BTnVFVVOR MXHJR|UxRTJ3IN88US=> NFzFSlQzOTl4NEO0NC=>
HL60 NILKOJRkgXSxdH;4bYNqfHliYYPzZZk> NHfQPG9,OTByIN88US=> NUGxWWV3TE2VTx?= M4fsfWlEPTB;OEmwJI5O MnfXNlE6PjR|NEC=
MV4;11 NWLVNpB6SXCxcITvd4l{KGG|c3H5 MXT+NVAxKM7:TR?= NVnmVJg1TE2VTx?= NIL3d21qdmS3Y3XzJIFxd3C2b4Ppdy=> NUXkeJFJOjF7NkSzOFA>
MOLM13 NUG2Onh7SXCxcITvd4l{KGG|c3H5 NFrFVWF,OTByIN88US=> NH;5Uo5FVVOR NIfwSGRqdmS3Y3XzJIFxd3C2b4Ppdy=> M33B[lIyQTZ2M{Sw
MV4;11 MVXGeY5kfGmxbjDhd5NigQ>? MkDiSG1UVw>? NVnKNZBl\GWlcnXhd4V{KHSqZTDy[YNzfWm2bXXueEBw\iCEUlSzM|Qh[W6mIHntdIFqemWmIILlZ5J2cXSvZX70JI9nKEOGS{mgZY5lKFCDRkGgeI8hfGinIITyZY5{[3KrcITpc45idCC|dHHyeEB{cXSn MkPmNlE6PjR|NEC=
PBMC MUPGeY5kfGmxbjDhd5NigQ>? M2LKVmROW09? MkLNbY5pcWKrdIOgTWwuPiC5aYToJJBKSzVyIH;mJFYvPw>? Ml3JNlI1OzdzMUW=
A2 Ml;4SpVv[3Srb36gZZN{[Xl? NEe2e3p,OTBizszN NUXrSnlFTE2VTx?= M{\WdpJm[WO2aY\heIV{KGyjdHXueEBJUVZvMR?= MnzGNlMzPTV{MUi=
A72 MnHvSpVv[3Srb36gZZN{[Xl? NYHvPXhHhjFyIN88US=> MXrEUXNQ M4PBTJJm[WO2aY\heIV{KGyjdHXueEBJUVZvMR?= MYSyN|I2PTJzOB?=
BC1 MmXyS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl? MUP+NUDPxE1? M2PVcmROW09? M4LBWGlEPTB;MkKwJI5O NYHyU4wyOjN5OUK0OFg>
BC3 M4PoO2dzd3e2aDDpcohq[mm2b4L5JIF{e2G7 M{jrc54yKM7:TR?= M1qyeWROW09? MWXJR|UxRTR4MDDuUS=> MXiyN|c6OjR2OB?=
BCBL1 MXHHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>? MYf+NUDPxE1? Ml3pSG1UVw>? MWHJR|UxRTN|MDDuUS=> NIjNVlEzOzd7MkS0PC=>
BJAB NH21Z21Iem:5dHigbY5pcWKrdH;yfUBie3OjeR?= M13BUJ4yKM7:TR?= NFHvOmhFVVOR M3jRXmlEPTB;OUewJI5O NWe1dohEOjN5OUK0OFg>
Namalwa MXvHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>? NVzQcFJuhjFizszN MXjEUXNQ MXLJR|UxRTl5MDDuUS=> MYqyN|c6OjR2OB?=
Jurkat MmO4S5Jwf3SqIHnubIljcXSxcomgZZN{[Xl? NF\wUHN,OSEQvF2= M4PQOmROW09? NF7VZpVKSzVyPUGyNlAhdk1? NF75dlAzOzd7MkS0PC=>
MM1S NET6PXdIem:5dHigbY5pcWKrdH;yfUBie3OjeR?= NIjHcpp,OSEQvF2= MlfLSG1UVw>? MkXJTWM2OD15NkCgcm0> NVTPXmpROjN5OUK0OFg>
U266 M2XnRWdzd3e2aDDpcohq[mm2b4L5JIF{e2G7 NFLuR4l,OSEQvF2= M1HlVGROW09? MXnJR|UxRTl3MDDuUS=> NH;z[GQzOzd7MkS0PC=>
UM-PEL-1 MoT3S5Jwf3SqIHnubIljcXSxcomgZZN{[Xl? NUm0XI97hjFizszN MoPnSG1UVw>? MVrJR|UxRTJzMDDuUS=> NE\hfpgzOzd7MkS0PC=>
UM-PEL-3 MVPHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>? MoTqglEh|ryP M3OwWmROW09? MXTJR|UxRTF6MDDuUS=> MWSyN|c6OjR2OB?=
BC1 MnW1SpVv[3Srb36gZZN{[Xl? M3nHbFUxOCCwTR?= NXLBb3RLTE2VTx?= NV7QXGczcW6mdXPld{Bk\WyuLXP5Z4xmKGG{cnXzeC=> M1WxdVI{Pzl{NES4
BC3 MYTGeY5kfGmxbjDhd5NigQ>? NVOxb|FFPTByIH7N Mn[3SG1UVw>? M1jVdIlv\HWlZYOgZ4VtdC2leXPs[UBienKnc4S= NXzzc4prOjN5OUK0OFg>
BC1 M131TmZ2dmO2aX;uJIF{e2G7 M{S4ZlgxOCCwTR?= M4SydGROW09? MX3y[YR2[2W|IHOtUZlkKHC{b4TlbY4hdGW4ZXzz M1jKWlI{Pzl{NES4
BC3 NH7Cc5lHfW6ldHnvckBie3OjeR?= Ml72PFAxKG6P MnrvSG1UVw>? M4DZOZJm\HWlZYOgZ{1OgWNicILveIVqdiCuZY\lcJM> NXz3VnZXOjN5OUK0OFg>
H929 MXjGeY5kfGmxbjDhd5NigQ>? M3;ub54yKM7:TR?= MWnEUXNQ NGnreGNqdmS3Y3XzJINmdGxiY4njcIUh[XK{ZYP0 NUTQWIhlOjR|M{W0PVk>
KMS12PE NFX5S3pHfW6ldHnvckBie3OjeR?= MnLyglEh|ryP NIn4d5pFVVOR NH\2UpJqdmS3Y3XzJINmdGxiY4njcIUh[XK{ZYP0 M2jsbFI1OzN3NEm5
KMS12BM M1XMTmZ2dmO2aX;uJIF{e2G7 MoTVglEh|ryP NVfxW2Q4TE2VTx?= M33YPIlv\HWlZYOgZ4VtdCCleXPs[UBienKnc4S= MXiyOFM{PTR7OR?=
KMS18 NHrhRmtHfW6ldHnvckBie3OjeR?= MXr+NUDPxE1? MUXEUXNQ Ml2zbY5lfWOnczDj[YxtKGO7Y3zlJIFzemW|dB?= MkHvNlQ{OzV2OUm=
KMS11 M{HmXGZ2dmO2aX;uJIF{e2G7 M1n2Zp4yKM7:TR?= NYOwN5NCTE2VTx?= NILzfJpqdmS3Y3XzJINmdGxiY4njcIUh[XK{ZYP0 M1nFfFI1OzN3NEm5
RPMI8226 NGK1OIhHfW6ldHnvckBie3OjeR?= NGfQNnN,OSEQvF2= NHPUTmZFVVOR MVzpcoR2[2W|IHPlcIwh[3mlbHWgZZJz\XO2 MU[yOFM{PTR7OR?=
H929 Mo\aRZBweHSxc3nzJIF{e2G7 MYr+NUDPxE1? NWHyXY1ETE2VTx?= M2T0eolv\HWlZYOgZ4VtdCCjcH;weI9{cXN? NUTjVWNvOjR|M{W0PVk>
KMS12PE MYDBdI9xfG:|aYOgZZN{[Xl? MlHrglEh|ryP Ml\WSG1UVw>? MlTkbY5lfWOnczDj[YxtKGGyb4D0c5Nqew>? M3i1WVI1OzN3NEm5
KMS12BM M{PLVGFxd3C2b4Ppd{Bie3OjeR?= NHjr[3J,OSEQvF2= NY\CXoVTTE2VTx?= NEDuRnFqdmS3Y3XzJINmdGxiYYDvdJRwe2m| NVvmZ5ZoOjR|M{W0PVk>
KMS18 MUnBdI9xfG:|aYOgZZN{[Xl? NHLQOmF,OSEQvF2= M{HKPGROW09? MV\pcoR2[2W|IHPlcIwh[XCxcITvd4l{ NXfrZmNWOjR|M{W0PVk>
KMS11 NFT3dJFCeG:ydH;zbZMh[XO|YYm= MojoglEh|ryP NUHRU5VlTE2VTx?= MlTrbY5lfWOnczDj[YxtKGGyb4D0c5Nqew>? MoPINlQ{OzV2OUm=
RPMI8226 NYKyR|lpSXCxcITvd4l{KGG|c3H5 NIfCSWp,OSEQvF2= M1Hr[2ROW09? NFPoPYVqdmS3Y3XzJINmdGxiYYDvdJRwe2m| NFPU[GczPDN|NUS5PS=>
U87MG MmDzSpVv[3Srb36gZZN{[Xl? NIXRcGh,OTBizszN M3vuSGROW09? MlLQdoVlfWOnczDVPFdOTyClZXzseYxieiCDVGCge4l1cCCLQ{WwJI9nKDFwMEWg{txO NYTybpVsOjR2OU[zPFE>
A172 M{jwWGZ2dmO2aX;uJIF{e2G7 MlLMglExKM7:TR?= M3r1RmROW09? MXzy[YR2[2W|IHPlcIx2dGG{IFHUVEB4cXSqIFnDOVAhd2ZiMT6yPEDPxE1? Mn\wNlQ1QTZ|OEG=
SW1783 NIDnS3JHfW6ldHnvckBie3OjeR?= M2fhUJ4yOCEQvF2= M4T0T2ROW09? MV7y[YR2[2W|IHPlcIx2dGG{IFHUVEB4cXSqIFnDOVAhd2ZiMj62PEDPxE1? MnvtNlQ1QTZ|OEG=
U87MG M4PVSGZ2dmO2aX;uJIF{e2G7 NGjaV|R,OTBizszN Mof5SG1UVw>? NXznb4FOcW6lcnXhd4V{KHC{b4DvdpRqd25ib3[gZ4VtdHNiaX6geIhmKEdzL2OgeJJidnOrdHnvci=> NUK5ZmhFOjR2OU[zPFE>
RAW267.4 MlzvSpVv[3Srb36gZZN{[Xl? NH3veVcyKM7:TR?= NIG5PGNFVVOR Mn;PdoVlfWOnczDJUE03KHC{b3T1Z5Rqd25iaX7keYNm\CCkeTDMVHM> NH;YcG0zPDh3OUCwPC=>
RAW267.4 MlfxSpVv[3Srb36gZZN{[Xl? M3fXOlEh|ryP NWXSVY0xTE2VTx?= M1LtXZJm\HWlZYOgeIhmKGG|c3;jbYF1cW:wIHLleJdm\W5iQmLEOEBidmRiYXPleJlt[XSnZDDwOlU> MXWyOFg2QTByOB?=
Me007 MWrHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>? MVT+NVAxKM7:TR?= MXrEUXNQ NIHBc3JqdmirYnn0d{B1cGViZ4Lve5Rp MXiyOFkxPjF|Nx?=
SK-Mel-28 M2\OcGdzd3e2aDDpcohq[mm2b4L5JIF{e2G7 MkW0glExOCEQvF2= MY\EUXNQ NGjQNmZqdmirYnn0d{B1cGViZ4Lve5Rp NXi4[WpKOjR7ME[xN|c>
Mel-RMU NVOyT3VuT3Kxd4ToJIlvcGmkaYTvdpkh[XO|YYm= NVvHU4dGhjFyMDFOwG0> NHjkcVZFVVOR Mn3jbY5pcWKrdIOgeIhmKGe{b4f0bC=> MWGyOFkxPjF|Nx?=
Mel-JD M1nkOmdzd3e2aDDpcohq[mm2b4L5JIF{e2G7 NX;Scng1hjFyMDFOwG0> NHywNmtFVVOR NInWeZhqdmirYnn0d{B1cGViZ4Lve5Rp MYiyOFkxPjF|Nx?=
Mel-RM NUnxTmFGT3Kxd4ToJIlvcGmkaYTvdpkh[XO|YYm= MVr+NVAxKM7:TR?= MonGSG1UVw>? MUjpcohq[mm2czD0bIUh\3Kxd4To NIqzcIgzPDlyNkGzOy=>
Me007 NWXKWIRDSXCxcITvd4l{KGG|c3H5 NXX0dos3hjFyMDFOwG0> NHWzRoRFVVOR Ml3WbY5lfWOnczDhdI9xfG:|aYO= NEWwdY0zPDlyNkGzOy=>
SK-Mel-28 MmrZRZBweHSxc3nzJIF{e2G7 NULEWJkzhjFyMDFOwG0> NIDCXGhFVVOR MYfpcoR2[2W|IHHwc5B1d3Orcx?= NUjiTnliOjR7ME[xN|c>
Mel-RMU NVrkVVRSSXCxcITvd4l{KGG|c3H5 MW\+NVAxKM7:TR?= NXvZVY9MTE2VTx?= NHfXdFNqdmS3Y3XzJIFxd3C2b4Ppdy=> NXjrUXpjOjR7ME[xN|c>
Mel-JD NFjGW2lCeG:ydH;zbZMh[XO|YYm= MVP+NVAxKM7:TR?= NGn5dlNFVVOR NUfFfXE5cW6mdXPld{BieG:ydH;zbZM> M1rudFI1QTB4MUO3
Mel-RM M4jDeWFxd3C2b4Ppd{Bie3OjeR?= NF;3WYl,OTByIN88US=> MWTEUXNQ NELuPVRqdmS3Y3XzJIFxd3C2b4Ppdy=> NEn6U4czPDlyNkGzOy=>
Me007 NXnpcWs6TnWwY4Tpc44h[XO|YYm= MVqxNEDPxE1? MYPEUXNQ MYDpcoR2[2W|IHPlcIwh[3mlbHWgZZJz\XO2IHL5JJVxemWpdXzheIlwdiCxZjDwNlE> MYmyOFkxPjF|Nx?=
SK-Mel-28 NH;ifopHfW6ldHnvckBie3OjeR?= NInwbmIyOCEQvF2= MUPEUXNQ MkWwbY5lfWOnczDj[YxtKGO7Y3zlJIFzemW|dDDifUB2eHKnZ4XsZZRqd25ib3[gdFIy NVvp[pZIOjR7ME[xN|c>
Mel-RMU MYPGeY5kfGmxbjDhd5NigQ>? NIm1RpMyOCEQvF2= MonUSG1UVw>? NUjDclBMcW6mdXPld{Bk\WyuIHP5Z4xmKGG{cnXzeEBjgSC3cILl[5Vt[XSrb36gc4YheDJz NXnVZ2kyOjR7ME[xN|c>
Mel-JD NVLUPZZITnWwY4Tpc44h[XO|YYm= MVuxNEDPxE1? MU\EUXNQ NW\FS5VPcW6mdXPld{Bk\WyuIHP5Z4xmKGG{cnXzeEBjgSC3cILl[5Vt[XSrb36gc4YheDJz NGf6SoMzPDlyNkGzOy=>
Mel-RM NVjLfXJETnWwY4Tpc44h[XO|YYm= NU\xdZQyOTBizszN MoHSSG1UVw>? M{fsO4lv\HWlZYOgZ4VtdCCleXPs[UBienKnc4SgZpkhfXC{ZXf1cIF1cW:wIH;mJJAzOQ>? NHLKfXQzPDlyNkGzOy=>
Me007 NXHEVoFTTnWwY4Tpc44h[XO|YYm= NUXrcZlCOTBizszN MWfEUXNQ NGXpNWJ2eHKnZ4XsZZRmeyCycn;hdI9xfG:2aXOgZY5lKGOnbHygZ5lkdGViYYLy[ZN1KGenbnXz NFzuOIkzPDlyNkGzOy=>
SK-Mel-28 NHjIUHlHfW6ldHnvckBie3OjeR?= NH21Z5IyOCEQvF2= MWXEUXNQ MYD1dJJm\3WuYYTld{Bxem:jcH;weI91cWNiYX7kJINmdGxiY4njcIUh[XK{ZYP0JIdmdmW| MnHpNlQ6ODZzM{e=
Mel-RMU M1\Hb2Z2dmO2aX;uJIF{e2G7 NWG3WW1[OTBizszN NVHWXGFTTE2VTx?= MojxeZBz\We3bHH0[ZMheHKxYYDvdJRwfGmlIHHu[EBk\WyuIHP5Z4xmKGG{cnXzeEBo\W6ncx?= MUKyOFkxPjF|Nx?=
Mel-JD NYHXS4EzTnWwY4Tpc44h[XO|YYm= MVmxNEDPxE1? NITQU2NFVVOR MXH1dJJm\3WuYYTld{Bxem:jcH;weI91cWNiYX7kJINmdGxiY4njcIUh[XK{ZYP0JIdmdmW| Ml63NlQ6ODZzM{e=
Mel-RM M{TWVWZ2dmO2aX;uJIF{e2G7 MnzZNVAh|ryP NUTWPHFYTE2VTx?= NF;aXJl2eHKnZ4XsZZRmeyCycn;hdI9xfG:2aXOgZY5lKGOnbHygZ5lkdGViYYLy[ZN1KGenbnXz M131VlI1QTB4MUO3

... Click to View More Cell Line Experimental Data

In vivo Administration of I-BET151 at 30 mg/kg/day significantly inhibits tumor growth of murine MLL-AF9 and human MLL-AF4 leukaemia in mice, and provides marked survival benefit. [1]

Protocol

Kinase Assay:

[1]

+ Expand

Fluorescence anisotropy (FP) ligand displacement assay:

All components are dissolved in buffer of composition 50 mM HEPES pH 7.4, 150 mM NaCl and 0.5 mM CHAPS with final concentrations of BRD 2/3/4 75 nM, fluorescent ligand 5 nM. 10 μL of this reaction mixture is added using a micro multidrop to wells containing 100 nL of various concentrations of I-BET151 or DMSO vehicle (1% final) in Greiner 384 well Black low volume microtitre plate and equilibrated in the dark for 60 minutes at room temperature. Fluorescence anisotropy is read in Envision (lex = 485 nm, lEM = 530 nm; Dichroic = 505 nM).
Cell Research:

[1]

+ Expand
  • Cell lines: MV4;11, MOLM13, NOMO1, RS4;11, HEL, HL60 and K562
  • Concentrations: Dissolved in DMSO, final concentrations ~100 μM
  • Incubation Time: 24, or 72 hours
  • Method:

    Cells are exposed to various concentrations of I-BET151 for 24 or 72 hours in 384-well or 96-well plates. For cell growth inhibition assays, plates are added with CellTiter-Glo reagent using a volume equivalent to the cell culture volume in the wells, shaken for approximately 2 minutes and chemiluminescent signal is read on the Analyst GT or EnVision Plate Reader. For cell proliferation assays, CellTiter-Aqueous One is added to each well and plates are incubated for 4 hours at 37 °C. Absorbance is read at 490 nm on a SpectraMax Gemini reader


    (Only for Reference)
Animal Research:

[1]

+ Expand
  • Animal Models: NOD-SCID mice injected intravenously with MV4;11 cells, and C57BL/6 mice injected intravenously with MLL-AF9 cells
  • Formulation: Dissolved in normal saline containing 5% (v/v) DMSO and 10% (w/v) Kleptose HPB
  • Dosages: ~30 mg/kg/day
  • Administration: Intraperitoneal injection
    (Only for Reference)

Solubility (25°C)

In vitro Ethanol 27 mg/mL (64.99 mM)
DMSO Insoluble
Water Insoluble

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 415.44
Formula

C23H21N5O3

CAS No. 1300031-49-5
Storage powder
Synonyms N/A

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Epigenetic Reader Domain Signaling Pathway Map

Epigenetic Reader Domain Inhibitors with Unique Features

Tags: buy I-BET151 (GSK1210151A) | I-BET151 (GSK1210151A) supplier | purchase I-BET151 (GSK1210151A) | I-BET151 (GSK1210151A) cost | I-BET151 (GSK1210151A) manufacturer | order I-BET151 (GSK1210151A) | I-BET151 (GSK1210151A) distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID